Ana C. DeCarvalho

Dr. Ana C. DeCarvalho

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Cancer Cell
Verified
Journal Article
Closed access
QWQianghu Wang
Qianghu Wang
BHBaoli Hu
Baoli Hu
XHXin Hu
Xin Hu
HKHoon Kim
Hoon Kim
MSMassimo Squatrito
Massimo Squatrito
RVRoel G.W. Verhaak
Roel G.W. Verhaak

23 April 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ADAna C. DeCarvalho
Ana C. DeCarvalho
HKHoon Kim
Hoon Kim
LPLaila M. Poisson
Laila M. Poisson
MWMary E. Winn
Mary E. Winn
CMClaudius Mueller
Claudius Mueller
RVRoel G. W. Verhaak
Roel G. W. Verhaak

8 May 2009 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
SLStephanie L. Lomonaco
Stephanie L. Lomonaco
SFSusan Finniss
Susan Finniss
CXCunli Xiang
Cunli Xiang
ADAna C. DeCarvalho
Ana C. DeCarvalho
FUFelix Umansky
Felix Umansky
CBChaya Brodie
Chaya Brodie

1 January 2018 in Cancer Cell
Verified
Journal Article
Closed access
QWQianghu Wang
Qianghu Wang
BHBaoli Hu
Baoli Hu
XHXin Hu
Xin Hu
HKHoon Kim
Hoon Kim
MSMassimo Squatrito
Massimo Squatrito
RVRoel G.W. Verhaak
Roel G.W. Verhaak

1 March 2014 in Neoplasia
Verified
Journal Article
Open access
ABArtem D. Berezovsky
Artem D. Berezovsky
LPLaila M. Poisson
Laila M. Poisson
DCDavid Cherba
David Cherba
CWCraig P. Webb
Craig P. Webb
ATAndrea D. Transou
Andrea D. Transou
ADAna C. DeCarvalho
Ana C. DeCarvalho
The high-mobility group-box transcription factor sex-determining region Y-box 2 (Sox2) is essential for the maintenance of stem cells from early development to adult tissues. Sox2 can reprogram differentiated cells into pluripotent cells in concert with other factors and is overexpressed in various cancers. In glioblastoma (GBM), Sox2 is a marker of cancer stemlike cells (CSCs) in neurosphere cultures and is associated with the proneural molecular subtype. Here, we report that Sox2 expression pattern in GBM tumors and patient-derived mouse xenografts is not restricted to a small percentage of cells and is coexpressed with various lineage markers, suggesting that its expression extends beyond CSCs to encompass more differentiated neoplastic cells across molecular subtypes. Employing a CSC derived from a patient with GBM and isogenic differentiated cell model, we show that Sox2 knockdown in the differentiated state abolished dedifferentiation and acquisition of CSC phenotype. Furthermore, Sox2 deficiency specifically impaired the astrocytic component of a biphasic gliosarcoma xenograft model while allowing the formation of tumors with sarcomatous phenotype. The expression of genes associated with stem cells and malignancy were commonly downregulated in both CSCs and serum-differentiated cells on Sox2 knockdown. Genes previously shown to be associated with pluripontency and CSCs were only affected in the CSC state, whereas embryonic stem cell self-renewal genes and cytokine signaling were downregulated, and the Wnt pathway activated in differentiated Sox2-deficient cells. Our results indicate that Sox2 regulates the expression of key genes and pathways involved in GBM malignancy, in both cancer stemlike and differentiated cells, and maintains plasticity for bidirectional conversion between the two states, with significant clinical implications.

1 July 2014 in Neoplasia
Verified
Journal Article
Open access
GBGregory J. Baker
Gregory J. Baker
VYViveka Nand Yadav
Viveka Nand Yadav
SMSebastien Motsch
Sebastien Motsch
CKCarl Koschmann
Carl Koschmann
ACAlexandra Calinescu
Alexandra Calinescu
PLPedro R. Lowenstein
Pedro R. Lowenstein
As glioma cells infiltrate the brain they become associated with various microanatomic brain structures such as blood vessels, white matter tracts, and brain parenchyma. How these distinct invasion patterns coordinate tumor growth and influence clinical outcomes remain poorly understood. We have investigated how perivascular growth affects glioma growth patterning and response to antiangiogenic therapy within the highly vascularized brain. Orthotopically implanted rodent and human glioma cells are shown to commonly invade and proliferate within brain perivascular space. This form of brain tumor growth and invasion is also shown to characterize de novo generated endogenous mouse brain tumors, biopsies of primary human glioblastoma (GBM), and peripheral cancer metastasis to the human brain. Perivascularly invading brain tumors become vascularized by normal brain microvessels as individual glioma cells use perivascular space as a conduit for tumor invasion. Agent-based computational modeling recapitulated biological perivascular glioma growth without the need for neoangiogenesis. We tested the requirement for neoangiogenesis in perivascular glioma by treating animals with angiogenesis inhibitors bevacizumab and DC101. These inhibitors induced the expected vessel normalization, yet failed to reduce tumor growth or improve survival of mice bearing orthotopic or endogenous gliomas while exacerbating brain tumor invasion. Our results provide compelling experimental evidence in support of the recently described failure of clinically used antiangiogenics to extend the overall survival of human GBM patients.